

On page 19, line 26 to page 20, line 12, please replace the current paragraph with the following:

Q3 Statistical analysis was performed with JMP 3.2.2 (SAS Institute, Inc.). The TaqMan data for the relative level of chemokine and chemokine receptors was log transformed and a one-way ANOVA performed. The log transformed of chemokine and chemokine receptor level was used as the dependent variable and the disease group was used as the independent variable. All groups were compared to the control group using a modified Student *t*-test, Dunnett's method.

On page 21, lines 11-13, please replace the current paragraph with the following:

Q4 All citations herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

IN THE CLAIMS

Please cancel claims 4, 5, and 7.

Please add claims 8-13 as follows:

- Q5
8. A method for treating an inflammatory bowel disease in a mammal, said method comprising administering to said mammal an effective amount of an agent to decrease signaling mediated by MIP-3 α .
 9. The method of Claim 8, wherein said inflammatory bowel disease is an ulcerative colitis.
 10. The method of Claim 8, wherein said inflammatory bowel disease is Crohn's disease.
 11. The method of Claim 8, wherein said agent decreases symptoms of the inflammatory bowel disease.
 12. The method of Claim 8, wherein said agent is an antibody that binds to MIP-3 α .
 13. The method of Claim 8, wherein said agent is an antibody that binds to CCR6.

REMARKS

SEQUENCE LISTING

A Sequence Listing detailing the sequences in the specification is provided herewith on paper and in computer-readable form. Applicant has also enclosed a statement indicating that the information recorded in computer readable form is identical to the enclosed written sequence listing and that the sequence listings do not go beyond the disclosure in the application as filed.